



Supplementary Materials: Toltrazuril-Loaded Polymeric Nanocapsules as a Promising Approach for the Preventive Control of Coccidiosis in Poultry

Lana Flávia Baron, Francisco Noé da Fonseca, Shaiana Salete Maciag, Franciana Aparecida Volpato Bellaver, Adriana Mércia Guaratini Ibeli, Marcos Antônio Zanella Mores, Gabryelle Furtado de Almeida, Silvia Stanisquaski Guterres, Ana Paula Almeida Bastos, Karina Paese

Table S1. Primers forward (F), reverse (R) and probes (P) used for *Eimeria* identification.

Species	Sequence source	Primer and probe sequences	Reference
<i>E. acervulina</i>	Ac-AD18-953	F: GCAGTCCGATGAAAGGTATTG R: GAAGCGAAATGTTAGGCCATCT P: [6FAM] ACAGTCCCCGCTGATGGTGTAACG[BHQ1] F: TCGTTGCATTGACAGATT R: TAGCGACTGCTCAAGGGTTT	15
<i>E. maxima</i>	EmMIC1	P: [6FAM] ATTGTCCAGCCAAGGTTCCCTTCG[BHQ1] F: TCGTCTTGGCTGGCTATT R: TAGCGACTGCTCAAGGGTTT	15
<i>E. tenella</i>	Tn-E03-1161	P: [6FAM] CTGGAAAGCGTCTCCTCAATGCG[BHQ1] F: TCATCACCCAAAGGGATT R: CAGAGAGTCGCCGTCACAGT	15
<i>E. spp</i>	5S rRNA	R: TTCATACTGCGTCTAATGCAC P: [6FAM] CGCCGCTTAACCTCGGAGTTAGATGGGAT [BHQ1]	16




Figure S1. Small intestine stained with Alcian Blue & PAS. Cells stained in blue are goblet cells (GC). VH: villus height; CD: crypt depth; VT: villus thickness; MT: mucosal thickness. Magnification, 200× (A) and 100× (B).




Figure S2. Light intensity graph obtained from particle tracking analysis. (A) Eudragit® S100 nanocapsules with toltrazuril (NCs_{100t}) or not (NCs₁₀₀); (B) Lipid core nanocapsules with toltrazuril (LNCT) or not (LNC).




Figure S3. Photomicrographs obtained from the NCs_{100t} formulation after 60 days of storage under refrigeration and keeping the formulation at rest. (A) normal light, (B) polarized light filter.

Table S2. Physicochemical parameters of nanoformulations containing toltrazuril after exposure to simulated gastric and intestinal media.

Parameter	LNC	NC _{S100}	LNCT	NC _{S100t}
z-average (nm)	Before	207 ± 1	154 ± 1	181 ± 2
	Gastric step	211 ± 3	152 ± 1	178 ± 1
	Intestinal step	207 ± 9	159 ± 1	176 ± 2
PDI	Before	0.145 ± 0.012	0.133 ± 0.013	0.091 ± 0.010
	Gastric step	0.171 ± 0.036	0.157 ± 0.021	0.100 ± 0.013
	Intestinal step	0.145 ± 0.044	0.140 ± 0.063	0.095 ± 0.008
Content (%)	Before	n.d.	n.d.	100*
	Gastric step	n.d.	n.d.	105.24 ± 7.94
	Intestinal step	n.d.	n.d.	99.61 ± 2.41

Values represent mean ± SD (n=3). LNC = blank lipid core nanocapsules; NC_{S100} = blank Eudragit® S100 nanocapsules; LNCT = toltrazuril-loaded lipid core nanocapsules; NC_{S100t} = toltrazuril-loaded Eudragit® S100 nanocapsules formulations; n.d. = not determined. *toltrazuril concentration before exposure to gastric and intestinal media was considered 100%.

Table S3. Nanotechnological properties of formulations after dilution in water.

		LNCT		LNC	
		0 h	24 h	0 h	24 h
Particle diameter (nm)	1 (1:10.5)	180.2 ± 4.3	179.3 ± 1.9	210.7 ± 2.5	207.7 ± 2.1
	2 (1:21)	180.1 ± 2.6	179.0 ± 0.6	-	-
	3 (1:42)	177.9 ± 1.2	179.0 ± 1.8	-	-
Drug content (%)	1 (1:10.5)	109.00 ± 5.18	-	-	-
	2 (1:21)	106.31 ± 6.76	-	-	-

	3 (1:42)	103.71 ± 10.50	-	-	-
Association efficiency (%)	1 (1:10.5)	99.88 ± 0.07	99.93 ± 0.01	-	-
	2 (1:21)	99.80 ± 0.08	99.86 ± 0.03	-	-
	3 (1:42)	99.26 ± 0.91	99.74 ± 0.03	-	-

Values represent mean \pm SD (n=3). LNC = blank lipid core nanocapsules; LNCt = toltrazuril-loaded lipid core nanocapsules.




Figure S4. Copy number/PCR of *Eimeria* spp. in cage excreta through days 17 to 21 of the experiment. G1 = control (-); G2 = control (+); G3 = Baycox® (7 mg/kg/day); G4 = LNCt (7 mg/kg/day); G5 = LNCt (3.5 mg/kg/day); G6 = LNCt (1.75 mg/kg/day); G7 = LNC (volume equivalent to G4).




Figure S5. Plot of median Likert score versus group. Error bars indicate the 95% confidence intervals for the median with the percentile method. *Adjusted p-value <0.05. G2 = control (+); G3 = Baycox® (7 mg/kg/day); G4 = LNCt (7 mg/kg/day); G5 = LNCt (3.5 mg/kg/day); G6 = LNCt (1.75 mg/kg/day); G7 = LNC (volume equivalent to G4).